INMD — InMode Ltd.
Is INMD overbought or oversold? Here is the current MarketMoodz read.
InMode Ltd. (INMD) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $13.15. The rating moved from Neutral to Oversold on November 7, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$13.15
- Last changeMoved from Neutral to Oversold on November 7, 2026
- SectorHealthcare
- IndustryMedical Devices
See all oversold Healthcare stocks →
AI analysis
InMode Ltd. (INMD) operates in the non-surgical aesthetic device market where secular demand for minimally invasive procedures supports a multi-year growth narrative. The company benefits from established product platforms and typically attractive margins tied to device sales and recurring consumables. Near-term performance is tightly linked to elective procedure volumes and practitioner capital spending; macro weakness or higher financing costs for clinics could weigh on device orders. Competition, regulatory outcomes, and concentrated product exposure add material downside risks. With limited social-sentiment signals and a market environment focused on policy clarity, outcomes over the next month will hinge on the company’s ability to sustain procedure demand and execute commercial initiatives. Monitor upcoming earnings, procedure-volume readouts, and any product or distribution updates for directional conviction.
Key factors
- Company market position in minimally invasive and energy-based aesthetic devices with recognizable product franchises and clinical adoption
- Historical margin profile driven by device ASPs and accessory/consumable follow-on sales supports profitability if procedure volumes stabilize
- Growth runway from global expansion, new product introductions, and secular demand for non-surgical cosmetic treatments
- Earnings sensitivity to elective procedure volumes—consumer spending trends and macro/interest-rate outlook materially affect near-term revenue visibility
- Limited social/research sentiment data available in the current window, reducing near-term crowd-driven volatility but increasing dependence on fundamentals and earnings cadence
- Opportunity for share gains if competitors face supply constraints or if InMode executes on commercial expansion and training initiatives
Risks
- High exposure to discretionary consumer spending and elective procedure volumes; economic weakness or consumer retrenchment would depress revenues
- Intense competition from other device makers and alternative aesthetic treatments that can pressure pricing and market share
- Regulatory and product-liability risk inherent to medical device companies; adverse events or recalls could materially impact sales and margin
- Concentration risk if a meaningful share of revenue derives from a limited number of products, geographies, or distributor relationships
- Supply-chain or manufacturing disruptions that could delay device shipments and slow revenue recognition
- Policy and rate environment uncertainty: higher rates and constrained access to financing for practices could reduce device purchases
See today's live rating, score and targets
Members see the live hourly rating for INMD — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.